In this Supplement
An in-depth look at how the science and clinical use of the first FDA-approved drug-coated balloon, LUTONIX® 035, continues to advance the treatment of PAD.
Experts weigh in on the ongoing trial data supporting the use of drug-coated balloons.
By J.A. Mustapha, MD; Patrick J. Geraghty, MD; Carlos Mena, MD; and Scott Trerotola, MD
An expert panel discusses the current role, data, and techniques for the use of drug-coated balloons in tackling PAD.
By J.A. Mustapha, MD; Chad R. Laurich, MD; Lawrence A. Garcia, MD; Patrick J. Geraghty, MD; and Prakash Krishnan, MD
Understanding the advantages and disadvantages that can result from different balloon technologies on the market.
By Kazuyuki Yahagi, MD; Frank D. Kolodgie, PhD; and Renu Virmani, MD
From a financial standpoint, DCBs have become the most attractive endovascular option for treating atherosclerosis in the superficial femoral artery.
By Mark W. Burket, MD
How will drug-coated balloons change the role of stenting in the SFA?